Sensodyne Pronamel Toothpaste Sensodyne Enamel-Pro Toothpaste
Sensodyne Pronamel Toothpaste Sensodyne Enamel-Pro Toothpaste
Sensodyne Pronamel Toothpaste Sensodyne Enamel-Pro Toothpaste
PL 00036/0105
PL 00036/0302
UKPAR
TABLE OF CONTENTS
Lay summary
Page 2
Scientific discussion
Page 3
Page 13
Page 14
Labelling-Patient information
Page 20
PL 00036/0105
PL 00036/0302
LAY SUMMARY
PL 00036/0105
PL 00036/0302
SCIENTIFIC DISCUSSION
TABLE OF CONTENTS
Introduction
Page 4
Pharmaceutical assessment
Page 5
Preclinical assessment
Page 9
Clinical assessment
Page 10
Page 12
INTRODUCTION
PHARMACEUTICAL ASSESSMENT
DRUG SUBSTANCE
Sodium fluoride
INN name: Sodium Fluoride
Other names: Natrii Fluoridum, Natrium Fluoratum
Molecular formula: NaF
Relative Molecular Weight: 41.99
Physical form: A white powder or colourless crystals
A satisfactory description of the manufacturing process for sodium fluoride is
provided.
An appropriate specification based on the European Pharmacopoeia has been
provided.
As the sodium fluoride used in the manufacture of the toothpaste is tested in
accordance with the requirements of the Ph. Eur, no validation data is needed.
Batch analysis results are provided in the form of Certificates of Analysis (CoA)
which state compliance with the Ph. Eur. (4th Edition).
The purity of sodium fluoride is determined a commercially sourced titrant.
A satisfactory specification for the packaging that comes into direct contact with
sodium fluoride has been provided, confirming that the packaging complies with
food contact regulations. A declaration from the manufacturer is provided
confirming compliance with Directive 2002/72/EC.
Satisfactory stability data are presented that support the proposed retest period.
Potassium nitrate
INN name: Potassium Nitrate
Other names: Kalii nitras
Molecular formula: KNO3 Relative Molecular Weight: 101.10
Physical form: A white crystalline powder, white granules or colourless crystals.
A satisfactory description of the manufacturing process for potassium nitrate is
provided.
An appropriate specification based on the European Pharmacopoeia has been
provided.
As the potassium nitrate used in the manufacture of the toothpaste is tested in
accordance with the requirements of the Ph. Eur, no validation data is needed.
Batch analysis results are provided in the form of Certificates of Analysis (CoA)
which state compliance with the Ph. Eur.
SENSODYNE PRONAMEL TOOTHPASTE AND SENSODYNE ENAMEL-PRO TOOTHPASTE, PL
00036/0105 AND PL 00036/0302
The manufacturer uses a USP and National Institute for Standards and
Technologies (NIST) reference standard for the assay of the potassium nitrate.
A satisfactory specification for the packaging that comes into contact with
potassium nitrate has been provided, confirming that the packaging complies with
food contact regulations.
Satisfactory stability data are presented that support the proposed retest period.
DRUG PRODUCT
Composition
The qualitative composition of Sensodyne Pronamel Toothpaste and Sensodyne
Enamel-Pro Toothpaste is as follows:
Ingredient Name
Reference to Standard
Active Ingredients
Potassium Nitrate
Ph Eur
Sodium Fluoride
Ph Eur
Excipients
Purified Water
Ph Eur
Ph Eur
Glycerol
Ph Eur
Ph Eur
Ph Eur
Ph Eur
Cocamidopropyl Betaine
HSE
HSE
Xanthan Gum
Ph Eur
Saccharin Sodium
Ph Eur
Titanium Dioxide
Ph Eur
Sodium Hydroxide
Ph Eur
product is stored below 30 C. In-use stability data was also generated, which
supported a shelf life of 6 months once the container has been opened.
Bioequivalence / bioavailability
No clinical studies were performed on the toothpastes. As this is a topical
preparation, this is not required by the guidelines.
Product literature
The SPCs for these products are satisfactory. The carton has been submitted to the
MHRA along with results of consultations with target patient groups ("user
testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The
results indicate that the carton information is well-structured and organised, easy
to understand and written in a comprehensive manner. The test shows that the
patients/users are able to act upon the information that it contains.
Assessors overall conclusions
Granting of Marketing Authorisations is acceptable.
PRECLINICAL ASSESSMENT
No new preclinical data have been supplied with this application and none are
required for applications of this type.
INTRODUCTION
Indications
The indications for these products are for the relief of dentinal hypersensitivity,
prevention of dental caries and protection against the effects of acid erosion of tooth
enamel.
Dose and dose regimen
The products are for dental use and are to be used 2-4 times a day, in place of
ordinary toothpaste.
CLINICAL PHARMACOLOGY
Pharmacokinetics
As stated in the CPMP notes for guidance on the non-clinical documentation of
medicinal products with well established use (CPMP/SWP/799/95), pharmacological
investigations, including pharmacokinetics, are normally not necessary. The
Applicant, in keeping with this guidance and the extensive history of safety of
potassium nitrate in dentrifice preparations, has not presented any additional
pharmacokinetic data.
Pharmacodynamics
No specific clinical pharmacology studies have been conducted on these products.
Bioequivalence
No bioavailability or bioequivalence studies have been conducted on these products.
CLINICAL EFFICACY
The combination of potassium nitrate and sodium fluoride in anti-caries/antisensitivity toothpaste is not novel. No specific clinical studies were conducted to
investigate the efficacy of the proposed products for the proposed indications of anticaries or anti-sensitivity because there is extensive literature which demonstrates that
fluoridated toothpastes significantly decrease the incidence of dental caries and that
fluoridated potassium nitrate toothpastes reduce dental sensitivity.
CLINICAL SAFETY
Formulations similar to the proposed products containing the same levels of sodium
fluoride and potassium nitrate are used worldwide by many millions of people each
year.
Based on the available preclinical data and the extensive in-use history of potassium
nitrate in toothpaste products, it can be clearly concluded that Sensodyne Pronamel
Toothpaste and Sensodyne Enamel-Pro Toothpaste are safe for their intended use and
are unlikely to cause significant undesirable effects when used as recommended.
10
The relatively low incidence of reporting of adverse events, when considered together
with patient exposure, confirm that potassium nitrate-containing toothpastes do not
cause significant undesirable effects when used within the dosage recommendations.
EXPERT REPORTS
A comprehensive clinical overview and biopharmaceutical summary for the proposed
products have been provided by the manufacturer. This appropriately addresses the
areas of clinical pharmacology, efficacy, safety and benefit/risk relevant to the
proposed product.
PRODUCT LITERATURE
SPC
It is noted that there are two SPCs, both for identical formulations of toothpaste but
under two distinct product names - Sensodyne Pronamel Toothpaste and Sensodyne
Enamel-Pro Toothpaste.
Patient Information Leaflet
Label
Information for patients is supplied on the product cartons. The information for
patients is clear and readable.
RISK BENEFIT
The Applicant has demonstrated that the active ingredients in the proposed products
have a well established use with an acceptable level of safety and with a recognised
efficacy.
CONCLUSION
These products can be granted Marketing Authorisations.
11
QUALITY
The important quality characteristics of the products are well defined and
controlled. The specifications and batch analytical results indicate consistency
from batch to batch. There are no outstanding quality issues that would have a
negative impact on the benefit/risk balance.
PRECLINICAL
No new preclinical data were submitted and none are required for applications of
this type.
EFFICACY AND SAFETY
The efficacy of potassium nitrate and sodium fluoride toothpastes has been well
documented in the past. No new or unexpected safety concerns arise from these
applications.
RISK BENEFIT ASSESSMENT
The quality of the products is acceptable and no new preclinical or clinical safety
concerns have been identified. The risk benefit ratio is considered to be positive.
12
PL 00036/0105
PL 00036/0302
13
PHARMACEUTICAL FORM
Toothpaste
Smooth, glossy slightly milky/transluscent white to cream paste at pH 7.1
4
4.1
CLINICAL PARTICULARS
Therapeutic indications
Relief of dentinal hypersensitivity
Prevention of dental caries
Protection against the effects of acid erosion of tooth enamel
4.2
4.3
Contraindications
Known allergic reactions to any of the active ingredients or excipients.
4.4
4.5
4.6
4.7
4.8
Undesirable effects
Very rarely, isolated cases of hypersensitivity type reactions such as
angioedema, oral and facial swelling have been reported in patients using
potassium nitrate containing toothpastes, particularly in patients who are
predisposed to hypersensitivity type reactions.
14
4.9
Overdose
No symptoms of overdose are known
5
5.1
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties
ATC Code Sodium Fluoride: A01AA01
ATC Code Potassium Nitrate: Not assigned
Potassium ions are thought to reduce hypersensitivity by interfering with
pulpal nerve conduction.
Sodium fluoride is an established anticaries agent, which prevents dental
caries. Fluoride inhibits caries and acid-erosion of dental enamel and dentine
by promoting tooth remineralisation/rehardening and inhibiting tooth
demineralisation/enamel softening. Fluoride in the oral cavity is incorporated
into hydroxyapatite in enamel to form fluoroapatite. Fluoroapatite is less
soluble than hydoxyapatite and more resistant to acid attack than the original
enamel that it replaces. Fluoride also inhibits the metabolism of acidproducing bacteria which are responsible for caries.
Dental type silicas act as polishing and cleaning agents to assist in the removal
of food remnants from the teeth. The grade of silica in the product provides an
abrasivity level which is low relative to most other toothpastes, but is within
that recommended in the International Standard ISO 11609 for dentifrice
products.
5.2
Pharmacokinetic properties
The product is applied topically and so the pharmacokinetics of the active
ingredients are not relevant to its efficacy.
5.3
6
6.1
PHARMACEUTICAL PARTICULARS
List of excipients
Purified Water,
Sorbitol, Liquid (non-crystallising),
Silica, Dental Type,
Glycerol,
Macrogols,
Xanthan Gum,
Titanium Dioxide (E171),
Cocamidopropyl Betaine,
Saccharin Sodium,
Sodium Hydroxide,
Mint Flavour 10926.
6.2
Incompatibilities
Not applicable
15
6.3
Shelf life
2 Years
After opening: 6 months
6.4
6.5
6.6
10
PL 00036/0302:
1
16
PHARMACEUTICAL FORM
Toothpaste
Smooth, glossy slightly milky/translucent white to cream paste at pH 7.1
4
4.1
CLINICAL PARTICULARS
Therapeutic indications
Relief of dentinal hypersensitivity
Prevention of dental caries
Protection against the effects of acid erosion of tooth enamel
4.2
4.3
Contraindications
Known allergic reactions to any of the active ingredients or excipients.
4.4
4.5
4.6
4.7
4.8
Undesirable effects
Very rarely, isolated cases of hypersensitivity type reactions such as
angioedema, oral and facial swelling have been reported in patients using
potassium nitrate containing toothpastes, particularly in patients who are
predisposed to hypersensitivity type reactions.
4.9
Overdose
No symptoms of overdose are known
5
5.1
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties
ATC Code Sodium Fluoride: A01AA01
ATC Code Potassium Nitrate: Not assigned
Potassium ions are thought to reduce hypersensitivity by interfering with
pulpal nerve conduction.
Sodium fluoride is an established anticaries agent, which prevents dental
caries. Fluoride inhibits caries and acid-erosion of dental enamel and dentine
17
Pharmacokinetic properties
The product is applied topically and so the pharmacokinetics of the active
ingredients are not relevant to its efficacy.
5.3
6
6.1
PHARMACEUTICAL PARTICULARS
List of excipients
Purified Water,
Sorbitol, Liquid (non-crystallising),
Silica, Dental Type,
Glycerol,
Macrogols,
Xanthan Gum,
Titanium Dioxide (E171),
Cocamidopropyl Betaine,
Saccharin Sodium,
Sodium Hydroxide,
Mint Flavour 10926.
6.2
Incompatibilities
Not applicable
6.3
Shelf life
2 Years
After opening: 6 months
6.4
6.5
18
20
10
19
LABELLING-PATIENT INFORMATION
PL 00036/0105
Label:
20
Carton:
21
PL 00036/0302
Label:
22
Carton:
23